Get alerts of updates about «Norwegian Medicines Agency investigating notification about death»
You have subscribed to alerts about:
Norwegian Medicines Agency investigating notification about death
It has not been concluded that there is any link between the vaccine and the death. The NIPH and the Norwegian Medicines Agency are investigating the incident further. The death concerns a younger person. There is no suspicion that the person died from a blood clot, as was the case in Denmark.
On Thursday, the NIPH decided to suspend use of the AstraZeneca vaccine pending investigations into a death following a blood clot in Denmark. The Norwegian Medicines Agency is now reviewing all reported suspected adverse reactions following vaccination with the AstraZeneca vaccine and other coronavirus vaccines.
In Norway, a total of 121,820 people have so far been vaccinated with the AstraZeneca vaccine. As of 9 February 2021, there have been 885 adverse reaction reports had been received, of which 31 were serious and 854 non-serious. No deaths have been reported previously.
Most notifications concern non-serious adverse reactions
Most of the adverse reaction notifications received concern common and expected adverse reactions, such as pain around the injection site, headache, general malaise with fever, fatigue, nausea and aches in the body. These adverse reactions are known from the studies which formed the basis for the vaccine approvals. These reactions normally appear on the first or second day after vaccination and last for around 2-3 days.
It can be difficult to know if an unwanted medical event that occurs shortly after vaccination is due to the vaccine or is just a coincidence. All the information about the incident will be reviewed as soon as it becomes available to assess any causal relationship.